Background & Aims Although there is a genetic predisposition to colorectal cancer (CRC), few of the genes that affect risk have been identified. We performed whole-exome sequence analysis of individuals in a high-risk family without mutations in genes previously associated with CRC risk to identify variants associated with inherited CRC. Methods We collected blood samples from 3 relatives with CRC in Spain (65, 62, and 40 years old at diagnosis) and performed whole-exome sequence analyses. Rare missense, truncating or splice-site variants shared by the 3 relatives were selected. We used targeted pooled DNA amplification followed by next generation sequencing to screen for mutations in candidate genes in 547 additional hereditary and/or early-onset CRC cases (502 additional families). We carried out protein-dependent yeast growth assays and transfection studies in the HT29 human CRC cell line to test the effects of the identified variants. Results A total of 42 unique or rare (population minor allele frequency below 1%) nonsynonymous genetic variants in 38 genes were shared by all 3 relatives. We selected the BRF1 gene, which encodes an RNA polymerase III transcription initiation factor subunit for further analysis, based on the predicted effect of the identified variant and previous association of BRF1 with cancer. Previously unreported or rare germline variants in BRF1 were identified in 11 of 503 CRC families, a significantly greater proportion than in the control population (34 of 4300). Seven of the identified variants (1 detected in 2 families) affected BRF1 mRNA splicing, protein stability, or expression and/or function. Conclusions In an analysis of families with a history of CRC, we associated germline mutations in BRF1 with predisposition to CRC. We associated deleterious BRF1 variants with 1.4% of familial CRC cases, in individuals without mutations in high-penetrance genes previously associated with CRC. Our findings add additional evidence to the link between defects in genes that regulate ribosome synthesis and risk of CRC.
Bibliographical noteFunding Information:
Funding This work was funded by the Spanish Ministry of Economy and Competitiveness, co-funded by FEDER funds—a way to build Europe (SAF2016–80888-R [LV], SAF2013–45836-R [XSP], SAF2015–68016-R [GC and MP], and Juan de la Cierva contract [PM]); Carlos III National Health Institute (PI16/00563 [CL], PI11/01439 [VM], PI14/00459 [MU], and CIBERONC); Government of Catalonia (2014SGR338, 2014SGR647); Catalan Department of Health (PERIS); the EU FP7 project ASSET (grant agreement 259348 [AV]); Joint BSC-IRB-CRG Program in Computational Biology; Severo Ochoa Award (SEV 2015-0493 [AV]) and Scientific Foundation Asociación Española Contra el Cáncer.
- Colon Cancer
- Familial Colorectal Cancer
- Protein Translation